Saturday 17 October 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS grew 82.0% and free cash flow fell 54.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow SXTP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.97 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.98 | 0.97 | 2.30 | 3.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.58) | (0.80) | (1.10) | (2.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.86 | (0.12) | 0.69 | 4.01 | |
EV/EBITDA |
0.00 | 0.02 | 0.00 | 0.00 | |
EV/Operating CF |
(0.37) | 0.02 | (0.11) | (0.55) | |
EV/FCF |
(0.37) | 0.02 | (0.11) | (0.54) | |
Quick Ratio |
2.18 | 1.77 | 1.96 | 0.99 | |
Current Ratio |
2.87 | 2.66 | 3.34 | 2.32 | |
Net Debt/EBITDA |
1.82 | 1.68 | 1.65 | 0.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.19 | 0.25 | 0.21 | 0.29 | |
Operating CF/Net income |
0.91 | 1.37 | 1.31 | 0.99 | |
Capex/Depreciation |
(0.38) | (2.00) | (0.59) | (1.04) | |
Interest Coverage |
(1,367.94) | (550.97) | (1,496.43) | (1,622.21) | |
Research and Development Expense of Revenue |
153.20% | 219.25% | 173.66% | 287.97% | |
Selling, General and Administrative Expense of Revenue |
285.02% | 448.10% | 1,165.89% | 831.75% | |
Intangible Assets out of Total Assets |
0.02 | 0.04 | 0.04 | 0.07 | |
Share Based Compensation of Revenue |
6.60% | 21.46% | 49.04% | 22.61% | |
Graham Net Nets |
0.73 | 2.14 | 1.40 | 0.42 | |
Graham Number |
0.00 | 48.31 | 19.86 | 11.38 | |
Earnings Yield |
103.50% | (553.22%) | (358.31%) | (123.32%) | |
Free Cash Flow Yield |
(126.54%) | (519.60%) | (273.04%) | (194.03%) | |
Revenue per Share |
0.58 | 0.47 | 0.09 | 0.08 | |
Operating CF per Share |
(2.30) | (2.53) | (1.59) | (0.84) | |
Capex per Share |
(0.03) | (0.20) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(2.32) | (2.73) | (1.61) | (0.87) | |
Cash per Share |
4.48 | 4.11 | 1.93 | 0.39 | |
Shareholders Equity per Share |
4.73 | 5.04 | 2.75 | 0.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.73 | 5.04 | 2.75 | 0.95 | |
Free Cash Flow |
(2.13) | (1.83) | (2.78) | (2.32) | |
Working Capital |
4.11 | 3.05 | 4.38 | 2.13 | |
Capital Expenditures |
(0.03) | (0.14) | (0.04) | (0.09) | |
Net Current Asset Value |
3.97 | 2.91 | 4.24 | 1.98 | |
EV/EBIT |
0.00 | 0.02 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.43 | 0.26 | 0.41 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.50 | 0.50 | 0.41 | 0.43 | |
Average Payables |
1.03 | 1.23 | 1.32 | 1.06 | |
Average Inventory |
0.49 | 0.55 | 0.84 | 0.84 | |
Average Assets |
7.06 | 5.56 | 6.37 | 4.23 | |
Average Common Equity |
(4.41) | (5.90) | (5.18) | (7.13) |
Columns are period end dates